Profiling mechanistic details of Isosorbide Di-(Linoleate/Oleate) and supporting its effectiveness for the treatment of xerotic pruritic skin
The breakdown of the epidermal barrier and consequent loss of skin hydration is a feature of skin ageing and eczematous dermatitis. Few treatments, however, resolve these underlying processes to provide full symptomatic relief.
Sytheon has evaluated topical effects of patented isosorbide di-(linoleate/oleate) (IDL) and compared with those of ethyl linoleate/oleate (doi:10.1016/j.jid.2020.09.029 ).
Both IDL and ethyl linoleate/oleate downregulated inflammatory gene expression, but IDL more effectively upregulated the expression of genes associated with keratinocyte differentiation (e.g., KRT1, GRHL2, SPRR4).
Consistent with this, IDL increased the abundance of epidermal barrier proteins (FLG and involucrin), hydration biomarker protein AQP-9 and prevented cytokine-mediated stratum corneum degradation.
IDL also downregulated the expression of unhealthy skin signature genes linked to the loss of epidermal homeostasis and uniquely repressed an IFN-inducible coexpression module activated in multiple skin diseases, including atopic dermatitis & psoriasis.
These results demonstrate mechanisms by which IDL improves skin hydration and epidermal barrier function, supporting IDL as an effective intervention for the treatment of xerotic pruritic skin.
Having secured broad patent coverage, defining the mechanism of IDL, and demonstrating its potential superiority over other linoleates, Sytheon stakes claim through its sister company, Symbionyx Pharmaceuticals Inc., to delve into dermatological market.
For more information, please contact: email@example.com